K-numberK250625
Device namePortable oxygen concentrator (W-R1(MAX)); Portable oxygen concentrator (W-R1); Portable oxygen concentrator (W-R2); Portable oxygen concentrator (W-R2(Lite))
ApplicantNanjing Yinuoji Medical Technology Co., Ltd.
Product codeCAW
Device classClass II
Decision dateAug 27, 2025
DecisionSubstantially Equivalent
Regulation868.5440
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Portable Oxygen Concentrator (models W-R1(MAX), W-R1, W-R2, W-R2(Lite)) is a Class II device that provides high-concentration supplemental oxygen (87%-95.5%) to adult patients requiring respiratory therapy on a prescription basis. It uses Pressure Swing Adsorption (PSA) technology with pulse-dose oxygen delivery and can be used at home, in institutions, vehicles, aircraft, and other transport modalities; it is not intended for life support.

Technological characteristics

The device uses the same fundamental molecular sieve/PSA technology and pulse-dose delivery mechanism as the predicate (Inogen Rove 6). Key differences include: USB Type-C power connector (vs. barrel jack in predicate); no external battery charger or Bluetooth/mobile app features; no DC power cable currently available; fixed rather than adjustable alarm volume; higher maximum pulse flow (1470 ml/min vs. 1260 ml/min); and slightly different oxygen purity specification (90% ±3%/+5.5% vs. 90% ±3%/+6%).

Test standards cited

ISO 80601-2-69:2020 and ISO 80601-2-67:2020 (oxygen concentrator safety and performance); IEC 60601-1:2005+AMD1:2012+AMD2:2020, IEC 60601-1-2:2014+AMD1:2020, IEC 60601-1-6:2010, IEC 60601-1-8:2006, IEC 60601-1-11:2015 (electrical safety and medical device standards); ISO 18562-2:2024 and ISO 18562-3:2024 (biocompatibility); IEC 62133-2:2017 (lithium battery safety); and internal bench testing for oxygen purity, pulse volume, trigger sensitivity, temperature/altitude/pressure limits, alarm functions, and battery life.

Substantial equivalence argument

The subject device shares the same intended use, product code (CAW), classification (Class II), and fundamental operating principle (PSA with pulse-dose delivery) as the Inogen Rove 6 predicate. Although the subject device has a higher maximum pulse flow (1470 vs. 1260 ml/min), the applicant demonstrates this remains within FDA-cleared parameters by citing the GCE Zen-O (K162433), which has even higher pulse flow (2000 ml/min). Performance differences (e.g., USB vs. barrel jack connector, absence of optional mobile app, fixed vs. adjustable alarm) are characterized as non-functional design choices that do not raise new safety or effectiveness questions. The device underwent the same battery of performance, biocompatibility, and electrical safety testing per relevant ISO/IEC standards, with all tests meeting required standards.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →